E-LIB Suche - Ergebnisse für: Mercuri, E

1

C.2 SUNFISH parts 1 and 2: 4-year efficacy and safety data ..:

Mah, JK ; Oskoui, M ; Day, JW...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 50 (2023) s2 - p. S51-S52 , 2023

Link: https://doi.org/10.1017/..

2

P36 Givinostat in Duchenne muscular dystrophy: effect on di..:

McDonald, C. ; Servais, L. ; Munell, F....
Neuromuscular Disorders. 33 (2023) - p. S106 , 2023

Link: https://doi.org/10.1016/..

3

P75 Revised Hammersmith Scale item achievement by functiona..:

Ramsey, D. ; Stimpson, G. ; Wolfe, A....
Neuromuscular Disorders. 33 (2023) - p. S135 , 2023

Link: https://doi.org/10.1016/..

4

P224 Effect of apitegromab on motor function at 36 months i..:

Crawford, T. ; Darras, B. ; Day, J....
Neuromuscular Disorders. 33 (2023) - p. S91 , 2023

Link: https://doi.org/10.1016/..

5

P219 Longitudinal disease progression in the Revised Hammer..:

Stimpson, G. ; Wolfe, A. ; Ramsey, D....
Neuromuscular Disorders. 33 (2023) - p. S90 , 2023

Link: https://doi.org/10.1016/..

6

P149 Delayed pulmonary progression in Golodirsen-treated pa..:

Iff, J. ; Tuttle, E. ; Liu, Y....
Neuromuscular Disorders. 33 (2023) - p. S85 , 2023

Link: https://doi.org/10.1016/..

7

P207 Scoliosis progression in spinal muscular atrophy type ..:

Coratti, G. ; Lenkowicz, J. ; Pera, M....
Neuromuscular Disorders. 33 (2023) - p. S86 , 2023

Link: https://doi.org/10.1016/..

8

P41 EMBARK, a Phase 3 trial evaluating safety and efficacy ..:

Muntoni, F. ; Mercuri, E. ; Schara-Schmidt, U....
Neuromuscular Disorders. 33 (2023) - p. S68-S69 , 2023

Link: https://doi.org/10.1016/..

9

P211 Intravenous and intrathecal onasemnogene abeparvovec g..:

Darras, B. ; Mercuri, E. ; Strauss, K....
Neuromuscular Disorders. 33 (2023) - p. S87 , 2023

Link: https://doi.org/10.1016/..

10

P35 Two-year clinical outcomes with fordadistrogene movapar..:

Shieh, P. ; Butterfield, R. ; Muntoni, F....
Neuromuscular Disorders. 33 (2023) - p. S105 , 2023

Link: https://doi.org/10.1016/..

11

P47 ENVISION, a phase 3, randomized trial evaluating the sa..:

Muntoni, F. ; Mercuri, E. ; McDonald, C....
Neuromuscular Disorders. 33 (2023) - p. S70 , 2023

Link: https://doi.org/10.1016/..

12

P234 Effect of Apitegromab on pedi-cat and promis-fatigue q..:

Crawford, T. ; Darras, B. ; Day, J....
Neuromuscular Disorders. 33 (2023) - p. S93-S94 , 2023

Link: https://doi.org/10.1016/..

13

P230 Safety update: Risdiplam clinical trial program for sp..:

Baranello, G. ; Chiriboga, C. ; Servais, L....
Neuromuscular Disorders. 33 (2023) - p. S92-S93 , 2023

Link: https://doi.org/10.1016/..

14

Socioeconomic differences in SARS-CoV-2-antigen contacts af..:

Beese, F ; Bartig, S ; Wachtler, B...
European Journal of Public Health. 33 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

15

P129 Givinostat in DMD: results of the Epidys study with pa..:

Vandenborne, K. ; Willcocks, R. ; Walter, G....
Neuromuscular Disorders. 33 (2023) - p. S79-S80 , 2023

Link: https://doi.org/10.1016/..